Legality and FDA approval are two different questions, and most people searching for one are really asking about the other. Federal law governs stem cell products in every state, and a small group of states have layered their own statutes on top. This guide covers the federal rule, the states with their own laws, and what those laws change.
TLDR Federal law, not state law, decides whether a stem cell product may be marketed in the United States. A state statute can shield a licensed physician from state board discipline, require a signed consent form, or mandate an advertising notice. It cannot approve a product or override the FDA. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy or trial.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease, and no state statute changes that. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Search results here contradict each other. One page says the therapy is legal in your state. The next says it is banned everywhere. Both can be quoting something real. The country answers this question on two levels at once.
The federal level asks what the product is. The state level asks what a licensed professional may do without risking a license. State legislatures regulate licensure and discipline. No state statute can approve a product, override FDA jurisdiction, or make an unapproved product legal to market.
Is Stem Cell Therapy Legal in the US?
There is no single yes or no. A narrow set of cellular products carry FDA approval for specific uses. Everything else is either investigational, studied under an FDA application, or unapproved and marketed outside that system.
FDA states the baseline in its consumer alert: “Stem cell products are regulated by FDA, and, generally, all stem cell products require FDA approval.” That page, current as of April 9, 2024, adds that no regenerative medicine products are approved for COVID-19, orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, autism, blindness, or chronic pain.
The agency is blunter on its patient information page: “If you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.” Permissive states get no exception.
The Federal Rule That Applies in Every State
The rule is 21 CFR Part 1271, titled “Human Cells, Tissues, and Cellular and Tissue-Based Products.” It is federal, so it reaches all fifty states. It sorts every human cell and tissue product into one of two lanes. Section 1271.10(a) sets four criteria. A product must meet all four to stay in the lighter lane.
| Criterion | What Section 1271.10(a) requires |
|---|---|
| First | It is minimally manipulated. |
| Second | It is intended for homologous use only, as reflected by labeling, advertising, or other indications of the manufacturer’s objective intent. |
| Third | Its manufacture involves no combination with another article, except water, crystalloids, or a sterilizing, preserving, or storage agent that raises no new clinical safety concerns. |
| Fourth | It has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or it does and is autologous, for a first-degree or second-degree blood relative, or for reproductive use. |
Look at the second criterion. Advertising is written into the regulation itself. How a product is promoted is part of how it gets classified.
Anything that fails those criteria and is not excepted under 1271.15 will be regulated as a drug, device, and/or biological product. That means an investigational new drug application to study it and a biologics license application to market it.
Adipose tissue sits inside this framework. FDA’s July 2020 guidance classifies adipose as a structural tissue and addresses stromal vascular fraction directly. Isolating it is “generally considered more than minimally manipulated because the processing breaks down and eliminates the adipocytes and the surrounding structural components that provide cushioning and support, thereby altering the original relevant characteristics.” Our explainer on FDA adipose regulation covers that classification.
Homologous use matters as much. FDA defines it at 1271.3(c). Homologous use is “the repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.” The guidance adds that using adipose tissue “for the treatment of a degenerative, inflammatory, or demyelinating disorder would generally be considered a non-homologous use.”
Legal Availability and FDA Approval Are Not the Same Thing
These are different tests applied by different governments. A state may decline to discipline a physician who offers an unapproved therapy. That says nothing about whether the product may lawfully be sold.
Two signals get mistaken for approval. The first is FDA establishment registration, which firms submit and list themselves. FDA says plainly that registration is not approval: “The inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.”
The second is approved cell therapies in general. FDA’s roster of approved cellular products, last updated August 18, 2026, lists no adipose-derived product for any disease. The only FDA-approved mesenchymal stromal cell product is RYONCIL, approved in December 2024. It is for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older, and it comes from bone marrow. Source tissue matters. Our overview of FDA tissue requirements covers the adipose rules.
Which States Have Passed Stem Cell Legislation?
States with an enacted stem cell specific statute include Nevada, California, Texas, Washington, Vermont, Utah, Florida, Wyoming, Georgia, and Tennessee, verified as of August 25, 2026. Read that group as a starting point, not a closed list. Other states have provisions this guide did not verify.
The table gives the law, year, citation, and what each statute does. Read the last column closely. The differences matter more than the similarities.
| State | Law | Year | Citation | What it does |
|---|---|---|---|---|
| Nevada | 2009 session | 2009 | NRS 629.300 to 629.390 | Permissive access; bars state boards from regulating or disciplining authorized activity |
| California | SB 512, amended by SB 1495 | 2017 | Bus. & Prof. Code 684 | Patient and advertising disclosure; $1,000 per violation |
| Texas | HB 810, “Charlie’s Law” | 2017 | Health & Safety Code ch. 1003, subch. B | Right-to-try style access, severe chronic or terminal illness, IRB oversight |
| Washington | 2018 c 216 s 1 | 2018 | RCW 18.130.420 | Informed consent, posted notice, advertising notice |
| Vermont | Act 61 (S.22) | 2021 | 18 V.S.A. 4502 | Notice, signed disclosure, advertising notice |
| Utah | SB 199, amended by SB 55 (2026) | 2024 | Utah Code 58-1-512 | Notice, consent, advertising notice; violation is unprofessional conduct |
| Florida | CS/CS/SB 1768, Ch. 2025-185 | 2025 | Fla. Stat. 458.3245 and 459.0127 | Authorization, advertising notice, consent |
| Wyoming | SF 0048, Ch. 64 | 2026 | W.S. 35-4-1101 to 35-4-1106 | Access, license-discipline shield, board registry |
| Georgia | HB 1275, Act 453 | 2026 | 2026 Ga. Laws Act 453 | Conditional permission, advertising notice, consent |
| Tennessee | HB 2246, Pub. Ch. 1016 | 2026 | 2026 Tenn. Pub. Ch. 1016 | Conditional permission, advertising notice, consent |
Not one of these statutes approves a product, and none creates a patient right to an unapproved therapy. Our state law map breaks down individual states.
What These State Laws Actually Do
They do three things in combination: they limit when a state board may discipline a physician, they require a signed consent form, and they dictate wording in advertising. That is the whole scope.
Georgia is the clearest recent example. HB 1275, enacted as 2026 Ga. Laws Act 453, was signed in May 2026 and took effect July 1, 2026. Its enrolled text grants a narrow permission. A physician, or a designated physician assistant or nurse practitioner, “may perform human stem cell therapy that is not approved by the FDA if such therapy is used for treatment or procedures that are within the scope of practice” of that professional. The permission holds only “so long as the patient is advised and signs a consent form.”
The Georgia penalty is professional discipline and nothing more. No criminal penalty, no fine, no private right of action. Georgia also requires a notice in “any form of advertisement.” It must be set in type no smaller than the largest type in the ad. It says the therapies “have not yet been approved by the FDA.”
Tennessee passed a close cousin. HB 2246 became Public Chapter 1016. Governor Bill Lee signed it on May 19, 2026, and it took effect July 1, 2026 for purposes other than rulemaking. Its permission reads: “A physician may perform stem cell therapy or regenerative medicine therapy that is not approved by the United States food and drug administration if the therapy is used for a treatment or procedure that is within the scope of practice of the physician.”
Most coverage of Tennessee describes the introduced bill, not the law. The enacted version dropped the Class E felony the draft carried and its four mandatory consent disclosures. Consent now requires only “a written consent form signed by the patient.” Georgia lists three disclosures the form must cover.
Texas took a different route. HB 810, known as Charlie’s Law, was signed June 12, 2017 and took effect September 1, 2017. It is not a general permission to sell anything.
Under Chapter 1003, the patient must have a severe chronic disease or terminal illness listed in the executive commissioner’s rules. The treating physician must determine that approved options are unavailable or unlikely to help. The therapy must be given directly by a certified physician, overseen by a qualifying institutional review board, at a licensed hospital, ambulatory surgical center, or medical school. HB 810 also created Penal Code 48.04. It is an offense to knowingly sell or transfer adult stem cells for valuable consideration for use in an investigational stem cell treatment.
Wyoming is stricter than the headlines suggest. Its Stem Cell Freedom Act requires the therapy be “conducted in accordance with a current institutional review board approval or is an investigational drug, biological product or device.” The physician must also register with the state board. California is narrower again. Business and Professions Code 684 excludes products that meet 21 CFR 1271.10 or 1271.15. It reaches only unapproved products in the drug and biologic lane.
Two Details That Change the State Map
Two facts get reported wrong often enough to flag. Arizona is not on the list. SB 1214 was vetoed on June 19, 2026. The Governor’s official legislative action update dated that day lists “SB1214 stem cells; regenerative therapy” under vetoed bills. A vetoed bill is not law.
Nevada needs precision in the other direction. It has had a nonembryonic cell statute since 2009, and NRS 629.340 bars state agencies and boards from regulating or disciplining authorized activity. What it does not have is a disclosure or consent mandate. Nevada has a stem cell law. It simply imposes no disclosure duty.
Nevada also wrote the clearest sentence on the limits of a state statute. NRS 629.350 reads: “Nothing in NRS 629.300 to 629.390, inclusive, shall be construed to indicate the status of any of the activities authorized pursuant to NRS 629.300 to 629.390, inclusive, as regards federal law.”
The most permissive statute in the country does not try to say anything about federal status. Tennessee’s law is silent on it. Georgia went the other way. It requires sourcing from facilities that follow current good manufacturing practices under 21 U.S.C. 301 et seq. and 21 C.F.R. Part 1271.
Why Legal Availability Gets Confused With Effectiveness
Because a bill passing looks like validation, and it is not. A legislature that tells a licensing board to stand down has made no finding about whether anything works. Nothing in these statutes weighs evidence. Georgia’s law even carries a savings clause. It says nothing in the law should be read to regulate, restrict, or prohibit stem cell research conducted in accordance with federal law. That is a legislature stepping back, not endorsing.
Where Adipose Tissue Banking Fits
Banking is a preservation decision, not a medical one. Save My Fat is a connector that links patients and providers with a U.S. tissue bank. It does not collect, process, store, or treat tissue, and it is not a clinic, a bank, or a medical practice.
Storing your own tissue does not make you eligible for anything. Whether banked adipose tissue could ever be used depends on three things: FDA regulatory status at that time, physician guidance, and whether an approved or investigational pathway exists. A permissive state statute changes none of that.
One federal detail is worth knowing. The autologous exception at 1271.90(a)(1) lifts the donor eligibility determination and the screening and testing that go with it, and nothing else. It does not lift registration, listing, current good tissue practice, labeling, or the 1271.10(a) criteria.
Frequently Asked Questions
Is stem cell therapy legal anywhere in the United States?
Approved cellular products are legal to market for their approved uses. Investigational products are lawfully studied under an FDA application. Unapproved products marketed outside that system are a different matter. FDA has stated that, generally, all stem cell products require FDA approval. A state statute does not change that.
Does a state law make an unapproved therapy safe or legal to buy?
No. State legislatures regulate licensure and discipline. A statute saying a physician “may perform” an unapproved therapy addresses state board discipline, not federal law. Section 1271.20 is a federal rule and it applies in all fifty states.
Which states have their own stem cell statute?
Nevada, California, Texas, Washington, Vermont, Utah, Florida, Wyoming, Georgia, and Tennessee were verified as of August 25, 2026. Other states may have provisions this guide did not verify. Do not read the group as complete, and confirm your own state’s law with an attorney.
What federal law applies regardless of my state?
21 CFR Part 1271. Its four criteria at 1271.10(a) decide which lane a product falls into. Section 1271.20 sends everything else into the drug, device, and biological product lane. That lane requires FDA applications to study a product and to market it.
Does banking adipose tissue give me access to these state programs?
No. Banking preserves your own tissue and nothing more. It does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program, and it does not connect anyone to a treatment pathway.
Key Takeaways
Federal law decides whether a stem cell product may be marketed, and it applies in all fifty states. Section 1271.10(a) sets four criteria, and 1271.20 sends anything that fails them into the drug and biologic lane. Ten states appear in the table above, and that group is not a closed list. Those statutes govern consent, advertising notices, and board discipline. None approves a product. Nevada’s own law says it indicates nothing about federal status. Banking adipose tissue preserves your own tissue and does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or bring their questions to the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about stem cell therapy or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: state stem cell laws.
